Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Endometrial Cancer Excellence Forum

Endometrial Cancer
Learning Library
Leaders in the field sharing authoritative insights and institutional best practices.

Mariana Gouveia, MD, DASA Oncologia
Videos
10/10/2024
Mariana Gouveia, MD, gives an overview of the use of antibody-drug conjugates for the treatment of patients with endometrial cancer.
Mariana Gouveia, MD, gives an overview of the use of antibody-drug conjugates for the treatment of patients with endometrial cancer.
Mariana Gouveia, MD, gives an...
10/10/2024
Oncology
Abigail Zamorano, MD, MPHS, UT Health Houston
Videos
10/08/2024
Abigail Zamorano, MD, MPHS, shares insights from a pilot study assessing a clinical algorithm, the the PREMM5 model, to evaluate a patient’s risk of carrying a Lynch Syndrome mutation, particularly in low-resource settings.
Abigail Zamorano, MD, MPHS, shares insights from a pilot study assessing a clinical algorithm, the the PREMM5 model, to evaluate a patient’s risk of carrying a Lynch Syndrome mutation, particularly in low-resource settings.
Abigail Zamorano, MD, MPHS,...
10/08/2024
Oncology
Steven Narod, MD, University of Toronto
Videos
09/12/2024
Steve Narod, MD, discusses the incidence of endometrial cancer among people who are BRCA mutation carriers.
Steve Narod, MD, discusses the incidence of endometrial cancer among people who are BRCA mutation carriers.
Steve Narod, MD, discusses the...
09/12/2024
Oncology
Alessandro Santin, MD, Yale Cancer Center
Videos
09/05/2024
Alessandro Santin, MD, shares insights from the endometrial cancer cohort of the TROPiCS-03 trial, which evaluated sacituzumab govetican among patients with advanced endometrial cancer who have been heavily pretreated.
Alessandro Santin, MD, shares insights from the endometrial cancer cohort of the TROPiCS-03 trial, which evaluated sacituzumab govetican among patients with advanced endometrial cancer who have been heavily pretreated.
Alessandro Santin, MD, shares...
09/05/2024
Oncology
Kathleen Moore, MD, Stephenson Cancer Center
Videos
08/26/2024
Kathleen Moore, MD, discusses the current treatment landscape for patients with advanced and recurrent endometrial cancer, considering the recent expanded indication of dostarlimab plus chemotherapy.
Kathleen Moore, MD, discusses the current treatment landscape for patients with advanced and recurrent endometrial cancer, considering the recent expanded indication of dostarlimab plus chemotherapy.
Kathleen Moore, MD, discusses...
08/26/2024
Oncology
BJ Rimel, MD, Cedars-Sinai Medical Center
Videos
08/23/2024
BJ Rimel, MD, shares insights on the recent FDA approval which expanded the previous indication for dostarlimab plus carboplatin-paclitaxel for all patients with primary advanced or recurrent endometrial cancer.
BJ Rimel, MD, shares insights on the recent FDA approval which expanded the previous indication for dostarlimab plus carboplatin-paclitaxel for all patients with primary advanced or recurrent endometrial cancer.
BJ Rimel, MD, shares insights on...
08/23/2024
Oncology
Matthew Powell, MD, Washington University School of Medicine in St Louis
Videos
08/09/2024
Matthew Powell, MD, discusses the phase 3 RUBY trial, in which dostarlimab plus carboplatin-paclitaxel improved overall survival among patients with endometrial cancer, when compared with placebo plus carboplatin and paclitaxel.
Matthew Powell, MD, discusses the phase 3 RUBY trial, in which dostarlimab plus carboplatin-paclitaxel improved overall survival among patients with endometrial cancer, when compared with placebo plus carboplatin and paclitaxel.
Matthew Powell, MD, discusses...
08/09/2024
Oncology
Aine Clements, MD
Conference Coverage
04/01/2024

Featuring Aine Clements, MD

Featuring Aine Clements, MD
Aine Clements, MD, discussed ancillary results from phase 3 GOG-0258 trial, as presented at the SGO 2024 Annual Meeting which demonstrated that molecular classification based on a modified ProMisE algorithm is prognostic in endometrial...
Aine Clements, MD, discussed ancillary results from phase 3 GOG-0258 trial, as presented at the SGO 2024 Annual Meeting which demonstrated that molecular classification based on a modified ProMisE algorithm is prognostic in endometrial...
Aine Clements, MD, discussed...
04/01/2024
Oncology
Bradley Corr, MD
Conference Coverage
03/21/2024

Featuring Bradley Corr, MD

Featuring Bradley Corr, MD
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting...
03/21/2024
Oncology
Joyce Barlin, MD, Women’s Cancer Care Associates, Albany, NY
Videos
04/05/2023
Joyce Barlin, MD, presents data from the Lunchbox trial at the SGO Annual Meeting on Women’s Cancer, comparing chemotherapy and radiation sandwich therapy vs chemotherapy alone for patients with advanced endometrial cancer.
Joyce Barlin, MD, presents data from the Lunchbox trial at the SGO Annual Meeting on Women’s Cancer, comparing chemotherapy and radiation sandwich therapy vs chemotherapy alone for patients with advanced endometrial cancer.
Joyce Barlin, MD, presents data...
04/05/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement